Corneal crosslinking (CXL) is a procedure designed to stabilise a progressive corneal condition known as keratoconus. In conditions like keratoconus and pellucid marginal degeneration, the cornea becomes weakened and bulges outward. This leads to a thin cornea, an irregular surface, and impaired vision.

In this procedure, Riboflavin (Vitamin B2) eye drops will be applied to the cornea, followed by exposure to ultraviolet light. This combination strengthens the cornea by enhancing the bonds between collagen fibres. While cross-linking (CXL) does not change vision, it helps prevent the progression of keratoconus and stabilizes vision.